DDInter1176 DDInter1082
An alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Methoxamine {u} (Compound) resembles {v} (Compound) Midodrine
Methoxamine {u} (Compound) binds {v} (Gene) ADRA1B
Methoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Methoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Methoxamine {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Methoxamine (Compound) resembles Midodrine (Compound)
Methoxamine (Compound) binds ADRA1B (Gene)
Methoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Methoxamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro
Methoxamine may lead to a major life threatening interaction when taken with Doxepin